TY - JOUR
T1 - Synthesis and evaluation of in vitro bioactivity for vesicular acetylcholine transporter inhibitors containing two carbonyl groups
AU - Tu, Zhude
AU - Wang, Wei
AU - Cui, Jinquan
AU - Zhang, Xiang
AU - Lu, Xiaoxia
AU - Xu, Jinbin
AU - Parsons, Stanley M.
N1 - Funding Information:
Financial support for these studies was provided by the National Institutes of Health under NS061025, NS075527 MH092797, and McDonnell Center for Systems Neuroscience.
PY - 2012/7/15
Y1 - 2012/7/15
N2 - To identify selective high-affinity ligands for the vesicular acetylcholine transporter (VAChT), we have incorporated a carbonyl group into the structures of trozamicol and prezamicol scaffolds, and also converted the secondary amines of the piperidines of trozamicols and prezamicols into amides. Of 18 new racemic compounds, 4 compounds displayed high affinity for VAChT (K i = 10-20 nM) and greater than 300-fold selectivity for VAChT over σ 1 and σ 2 receptors, namely (4-(4-fluorobenzoyl)-4′-hydroxy- [1,3′-bipiperidin]-1′-yl)(3-methylthiophen-2-yl)methanone oxalate (9g) (K i-VAChT = 11.4 nM, VAChT/σ 1 = 1063, VAChT/σ 2 = 370), (1′-benzoyl-4′-hydroxy-[1, 3′-bipiperidin]-4-yl)(4-methoxyphenyl)methanone oxalate (10c) (K i-VAChT = 15.4 nM, VAChT/σ 1 = 374, VAChT/σ 2 = 315), (4′-hydroxy-1′-(thiophene-2- carbonyl)-[1,3′-bipiperidin]-4-yl)(4-methoxyphenyl)methanone oxalate (10e) (K i-VAChT = 19.0 nM, VAChT/σ 1 = 1787, VAChT/σ 2 = 335), and (4′-hydroxy-1′-(3- methylthiophene-2-carbonyl)-[1,3′-bipiperidin]-4-yl)(4-methoxyphenyl) methanone oxalate (10g) (K i-VAChT = 10.2 nM, VAChT/σ 1 = 1500, VAChT/σ 2 = 2030). These four compounds can be radiosynthesized with C-11 or F-18 to validate their possibilities of serving as PET probes for quantifying the levels of VAChT in vivo.
AB - To identify selective high-affinity ligands for the vesicular acetylcholine transporter (VAChT), we have incorporated a carbonyl group into the structures of trozamicol and prezamicol scaffolds, and also converted the secondary amines of the piperidines of trozamicols and prezamicols into amides. Of 18 new racemic compounds, 4 compounds displayed high affinity for VAChT (K i = 10-20 nM) and greater than 300-fold selectivity for VAChT over σ 1 and σ 2 receptors, namely (4-(4-fluorobenzoyl)-4′-hydroxy- [1,3′-bipiperidin]-1′-yl)(3-methylthiophen-2-yl)methanone oxalate (9g) (K i-VAChT = 11.4 nM, VAChT/σ 1 = 1063, VAChT/σ 2 = 370), (1′-benzoyl-4′-hydroxy-[1, 3′-bipiperidin]-4-yl)(4-methoxyphenyl)methanone oxalate (10c) (K i-VAChT = 15.4 nM, VAChT/σ 1 = 374, VAChT/σ 2 = 315), (4′-hydroxy-1′-(thiophene-2- carbonyl)-[1,3′-bipiperidin]-4-yl)(4-methoxyphenyl)methanone oxalate (10e) (K i-VAChT = 19.0 nM, VAChT/σ 1 = 1787, VAChT/σ 2 = 335), and (4′-hydroxy-1′-(3- methylthiophene-2-carbonyl)-[1,3′-bipiperidin]-4-yl)(4-methoxyphenyl) methanone oxalate (10g) (K i-VAChT = 10.2 nM, VAChT/σ 1 = 1500, VAChT/σ 2 = 2030). These four compounds can be radiosynthesized with C-11 or F-18 to validate their possibilities of serving as PET probes for quantifying the levels of VAChT in vivo.
KW - CNS disorders
KW - Parkinson's disease
KW - VAChT
KW - Vesamciol
KW - σ Receptor
UR - http://www.scopus.com/inward/record.url?scp=84863185156&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2012.05.045
DO - 10.1016/j.bmc.2012.05.045
M3 - Article
C2 - 22739089
AN - SCOPUS:84863185156
SN - 0968-0896
VL - 20
SP - 4422
EP - 4429
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 14
ER -